CoChat
Sign Up
Cited by 527

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Advances in Oral Drug Delivery for Regional Targeting in the Gastrointestinal Tract - Influence of Physiological, Pathophysiological and Pharmaceutical Factors

Hua, Susan·2020·Frontiers in Pharmacology
DOI 10.3389/fphar.2020.00524PMC PMC7212533
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2020.00524

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 12 references

Research works printed but not linked: 251

  1. Acosta, 2009, Bioavailability of nanoparticles in nutrient and nutraceutical delivery, Curr. Opin. Colloid Interface Sci., 14, 3, 10.1016/j.cocis.2008.01.002 · DOI
  2. Ahmad, 2018, Improvement of oral efficacy of Irinotecan through biodegradable polymeric nanoparticles through in vitro and in vivo investigations, J. Microencapsul., 35, 327, 10.1080/02652048.2018.1485755 · DOI
  3. Al-Gousous, 2017, Unpredictable Performance of pH-Dependent Coatings Accentuates the Need for Improved Predictive in Vitro Test Systems, Mol. Pharm., 14, 4209, 10.1021/acs.molpharmaceut.6b00877 · DOI
  4. Ali, 2014, Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases, J. Control Release, 183, 167, 10.1016/j.jconrel.2014.03.039 · DOI
  5. Allen, 2011, Ansel"s pharmaceutical dosage forms and drug delivery systems.
  6. Anderson, 2001, Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage form, Pharmaceut. Res., 18, 316, 10.1023/A:1011002913601 · DOI
  7. Antoni, 2014, Intestinal barrier in inflammatory bowel disease, World J. Gastroenterol., 20, 1165, 10.3748/wjg.v20.i5.1165 · DOI
  8. Atuma, 2001, The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo, Am. J. Physiol. Gastrointest Liver Physiol., 280, G922, 10.1152/ajpgi.2001.280.5.G922 · DOI
  9. Awasthi, 2016, Decades of research in drug targeting to the upper gastrointestinal tract using gastroretention technologies: where do we stand, Drug Deliv., 23, 378, 10.3109/10717544.2014.936535 · DOI
  10. Banerjee, 2017, Intestinal patch systems for oral drug delivery, Curr. Opin. Pharmacol., 36, 58, 10.1016/j.coph.2017.08.005 · DOI
  11. Banerjee, 2016, Intestinal mucoadhesive devices for oral delivery of insulin, Bioengineering Trans. Med., 1, 338, 10.1002/btm2.10015 · DOI
  12. Banerjee, 2016, Role of nanoparticle size, shape and surface chemistry in oral drug delivery, J. Control Release, 238, 176, 10.1016/j.jconrel.2016.07.051 · DOI
  13. Banerjee, 2017, Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives, Drug Discovery Today, 22, 1224, 10.1016/j.drudis.2017.05.006 · DOI · Paper page
  14. Bannunah, 2014, Mechanisms of nanoparticle internalization and transport across an intestinal epithelial cell model: effect of size and surface charge, Mol. Pharm., 11, 4363, 10.1021/mp500439c · DOI
  15. Bardonnet, 2006, Gastroretentive dosage forms: overview and special case of Helicobacter pylori, J. Control Release, 111, 1, 10.1016/j.jconrel.2005.10.031 · DOI
  16. Bargoni, 1998, Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats, Pharmaceut. Res., 15, 745, 10.1023/A:1011975120776 · DOI
  17. Beloqui, 2013, Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis, Int. J. Pharm., 454, 775, 10.1016/j.ijpharm.2013.05.017 · DOI
  18. Beloqui, 2014, pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease, Int. J. Pharm., 203, 10.1016/j.ijpharm.2014.07.009 · DOI
  19. Beloqui, 2016, Mechanisms of transport of polymeric and lipidic nanoparticles across the intestinal barrier, Adv. Drug Delivery Rev., 106, 242, 10.1016/j.addr.2016.04.014 · DOI
  20. Bhavsar, 2007, Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS), J. Control Release, 119, 339, 10.1016/j.jconrel.2007.03.006 · DOI
  21. Bratten, 2006, New directions in the assessment of gastric function: clinical applications of physiologic measurements, Digestive Dis., 24, 252, 10.1159/000092878 · DOI · Paper page
  22. Britton, 2014, Role of the intestinal microbiota in resistance to colonization by Clostridium difficile, Gastroenterology, 146, 1547, 10.1053/j.gastro.2014.01.059 · DOI · Paper page
  23. Brunton, 2018, Goodman & Gilman"s: The Pharmacological Basis of Therapeutics.
  24. Buhmann, 2007, Assessment of colonic transit time using MRI: a feasibility study, Eur. Radiol., 17, 669, 10.1007/s00330-006-0414-z · DOI · Paper page
  25. Byrne, 2007, Patient preferences between surgical and medical treatment in Crohn's disease, Dis. Colon Rectum., 50, 586, 10.1007/s10350-006-0847-0 · DOI
  26. Camenisch, 1998, Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight, Eur. J. Pharmaceut. Sci., 6, 317, 10.1016/S0928-0987(97)10019-7 · DOI
  27. Caraballo, 2010, Factors affecting drug release from hydroxypropyl methylcellulose matrix systems in the light of classical and percolation theories, Expert Opin. Drug Delivery, 7, 1291, 10.1517/17425247.2010.528199 · DOI
  28. Carlson, 1999, Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion, Am. J. Gastroenterol., 94, 1876, 10.1111/j.1572-0241.1999.01223.x · DOI
  29. Cavalli, 2003, Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin, J. Pharm. Sci., 92, 1085, 10.1002/jps.10368 · DOI
  30. Chen, 2013, Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules, Adv. Drug Delivery Rev., 65, 865, 10.1016/j.addr.2012.10.010 · DOI
  31. Chionh, 2009, M-cell targeting of whole killed bacteria induces protective immunity against gastrointestinal pathogens, Infect. Immun., 77, 2962, 10.1128/IAI.01522-08 · DOI
  32. Chowdhury, 2011, Fluids and gastrointestinal function, Curr. Opin. Clin. Nutr. Metab. Care, 14, 469, 10.1097/MCO.0b013e328348c084 · DOI
  33. Clark, 2001, Targeting polymerised liposome vaccine carriers to intestinal M cells, Vaccine, 20, 208, 10.1016/S0264-410X(01)00258-4 · DOI
  34. Coco, 2013, Drug delivery to inflamed colon by nanoparticles: comparison of different strategies, Int. J. Pharm., 440, 3, 10.1016/j.ijpharm.2012.07.017 · DOI · Paper page
  35. Collnot, 2012, Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa, J. Control Release, 161, 235, 10.1016/j.jconrel.2012.01.028 · DOI
  36. Colombo, 1995, Drug diffusion front movement is important in drug release control from swellable matrix tablets, J. Pharm. Sci., 84, 991, 10.1002/jps.2600840816 · DOI
  37. Colombo, 2000, Swellable matrices for controlled drug delivery: gel-layer behaviour, mechanisms and optimal performance, Pharmaceut. Sci. Technol. Today, 3, 198, 10.1016/S1461-5347(00)00269-8 · DOI
  38. Cornick, 2015, Roles and regulation of the mucus barrier in the gut, Tissue Barriers, 3, 10.4161/21688370.2014.982426 · DOI
  39. Coupe, 1991, Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects, Pharmaceut. Res., 8, 360, 10.1023/A:1015849700421 · DOI · Paper page
  40. Cummings, 1991, The control and consequences of bacterial fermentation in the human colon, J. Appl. Bacteriol., 70, 443, 10.1111/j.1365-2672.1991.tb02739.x · DOI · Paper page
  41. De Coen, 2016, pH-Degradable Mannosylated Nanogels for Dendritic Cell Targeting, Biomacromolecules, 17, 2479, 10.1021/acs.biomac.6b00685 · DOI
  42. des Rieux, 2005, Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium, Eur. J. Pharmaceut. Sci., 25, 455, 10.1016/j.ejps.2005.04.015 · DOI
  43. des Rieux, 2006, Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach, J. Control Release, 116, 1, 10.1016/j.jconrel.2006.08.013 · DOI · Paper page
  44. Desai, 1996, Gastrointestinal uptake of biodegradable microparticles: effect of particle size, Pharmaceut. Res., 13, 1838, 10.1023/A:1016085108889 · DOI
  45. Du, 2018, The effect of surface charge on oral absorption of polymeric nanoparticles, Biomater. Sci., 6, 642, 10.1039/C7BM01096F · DOI
  46. Edsbacker, 2004, Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease, Clin. Pharmacokinet., 43, 803, 10.2165/00003088-200443120-00003 · DOI
  47. Eldridge, 1989, Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response, Adv. Exp. Med. Biol., 251, 191, 10.1007/978-1-4757-2046-4_18 · DOI
  48. Eldridge, 1990, Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches, J. Control Release, 11, 205, 10.1016/0168-3659(90)90133-E · DOI
  49. Fallingborg, 1993, Very low intraluminal colonic pH in patients with active ulcerative colitis, Digestive Dis. Sci., 38, 1989, 10.1007/BF01297074 · DOI
  50. Fallingborg, 1998, Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn's disease, Digestive Dis. Sci., 43, 702, 10.1023/A:1018893409596 · DOI
  51. Felton, 2013, An update on pharmaceutical film coating for drug delivery, Expert Opin. Drug Deliv., 10, 421, 10.1517/17425247.2013.763792 · DOI
  52. Fievez, 2009, Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination, Eur. J. Pharm. Biopharm, 73, 16, 10.1016/j.ejpb.2009.04.009 · DOI
  53. Fonte, 2011, Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin, Drug Deliv. Trans. Res., 1, 299, 10.1007/s13346-011-0023-5 · DOI
  54. Foster, 1998, Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo, Vaccine, 16, 536, 10.1016/S0264-410X(97)00222-3 · DOI
  55. Frank, 2007, Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases, Proc. Natl. Acad. Sci. U. States A., 104, 13780, 10.1073/pnas.0706625104 · DOI · Paper page
  56. Frey, 1996, Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting, J. Exp. Med., 184, 1045, 10.1084/jem.184.3.1045 · DOI · Paper page
  57. Gareb, 2016, Development of a zero-order sustained-release tablet containing mesalazine and budesonide intended to treat the distal gastrointestinal tract in inflammatory bowel disease, Eur. J. Pharm. Biopharm., 103, 32, 10.1016/j.ejpb.2016.03.018 · DOI
  58. Gartner, 2002, The forestomach of rats and mice, an effective device supporting digestive metabolism in muridae, J. Exp. Anim. Sci., 42, 1, 10.1016/S0939-8600(02)80002-5 · DOI
  59. Gazzaniga, 2006, Time-controlled oral delivery systems for colon targeting, Expert Opin. Drug Deliv., 3, 583, 10.1517/17425247.3.5.583 · DOI
  60. Goto, 2004, Pharmaceutical design of a novel colon-targeted delivery system using two-layer-coated tablets of three different pharmaceutical formulations, supported by clinical evidence in humans, J. Control Release, 97, 31, 10.1016/j.jconrel.2004.02.023 · DOI
  61. Gracie, 2012, Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea, Neurogastroenterol. Motil., 24, 983, 10.1111/j.1365-2982.2012.01953.x · DOI
  62. Griffin, 2016, Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs, Adv. Drug Delivery Rev., 106, 367, 10.1016/j.addr.2016.06.006 · DOI
  63. Grover, 2008, Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress, Neurogastroenterol. Motil., 20, 998, 10.1111/j.1365-2982.2008.01142.x · DOI · Paper page
  64. Gupta, 2016, Delivery of Exenatide and Insulin Using Mucoadhesive Intestinal Devices, Ann. Biomed. Engineering, 44, 1993, 10.1007/s10439-016-1558-x · DOI
  65. Hamman, 2007, Targeting receptors, transporters and site of absorption to improve oral drug delivery, Drug Target Insights, 2, 71, 10.1177/117739280700200003 · DOI
  66. Han, 2012, Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system, Eur. J. Pharmaceut. Sci., 46, 500, 10.1016/j.ejps.2012.04.002 · DOI
  67. Hao, 2014, Sinking-magnetic microparticles prepared by the electrospray method for enhanced gastric antimicrobial delivery, Mol. Pharm., 11, 1640, 10.1021/mp5000339 · DOI
  68. Harel, 2011, Enhanced transferrin receptor expression by proinflammatory cytokines in enterocytes as a means for local delivery of drugs to inflamed gut mucosa, PloS One, 6, 10.1371/journal.pone.0024202 · DOI
  69. Hatton, 2018, All disease begins in the gut: Influence of gastrointestinal disorders and surgery on oral drug performance, Int. J. Pharm., 548, 408, 10.1016/j.ijpharm.2018.06.054 · DOI
  70. Hatton, 2019, Gut reaction: impact of systemic diseases on gastrointestinal physiology and drug absorption, Drug Discovery Today, 24, 417, 10.1016/j.drudis.2018.11.009 · DOI
  71. Hebden, 2000, Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis, Alimentary Pharmacol. Ther., 14, 155, 10.1046/j.1365-2036.2000.00697.x · DOI
  72. Helander, 2014, Surface area of the digestive tract - revisited, Scand. J. Gastroenterol., 49, 681, 10.3109/00365521.2014.898326 · DOI · Paper page
  73. Hellmund, 2015, Systematic adjustment of charge densities and size of polyglycerol amines reduces cytotoxic effects and enhances cellular uptake, Biomater. Sci., 3, 1459, 10.1039/C5BM00187K · DOI
  74. Hillyer, 2001, Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles, J. Pharm. Sci., 90, 1927, 10.1002/jps.1143 · DOI
  75. Hofmann, 2014, Mass spectrometry and imaging analysis of nanoparticle-containing vesicles provide a mechanistic insight into cellular trafficking, ACS Nano, 8, 10077, 10.1021/nn502754c · DOI
  76. Homayun, 2019, Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals, Pharmaceutics, 11, 129, 10.3390/pharmaceutics11030129 · DOI · Paper page
  77. Hoque, 2012, New advances in the pathophysiology of intestinal ion transport and barrier function in diarrhea and the impact on therapy, Expert Rev. Anti-infect. Ther., 10, 687, 10.1586/eri.12.47 · DOI
  78. Hovgaard, 1996, Current applications of polysaccharides in colon targeting, Crit. Rev. Ther. Drug Carrier Syst., 13, 185, 10.1615/CritRevTherDrugCarrierSyst.v13.i3-4.10 · DOI
  79. Hu, 2000, Application of a biomagnetic measurement system (BMS) to the evaluation of gastrointestinal transit of intestinal pressure-controlled colon delivery capsules (PCDCs) in human subjects, Pharmaceut. Res., 17, 160, 10.1023/A:1007561129221 · DOI · Paper page
  80. Hu, 2015, The endosomal-lysosomal system: from acidification and cargo sorting to neurodegeneration, Trans. Neurodegeneration, 4, 18, 10.1186/s40035-015-0041-1 · DOI
  81. Hu, 2016, Evidence does not support absorption of intact solid lipid nanoparticles via oral delivery, Nanoscale, 8, 7024, 10.1039/C5NR07474F · DOI
  82. Hua, 2015, Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue, Nanomedicine, 11, 1117, 10.1016/j.nano.2015.02.018 · DOI · Paper page
  83. Hua, 2018, Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization, Front. Pharmacol., 9, 10.3389/fphar.2018.00790 · DOI
  84. Hua, 2014, Orally administered liposomal formulations for colon targeted drug delivery, Front. Pharmacol., 5, 10.3389/fphar.2014.00138 · DOI
  85. Ibekwe, 2008, Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems, Pharmaceut. Res., 25, 1828, 10.1007/s11095-008-9580-9 · DOI · Paper page
  86. Irache, 1994, In vitro study of lectin-latex conjugates for specific bioadhesion, J. Control Release, 31, 181, 10.1016/0168-3659(94)00033-6 · DOI
  87. Jain, 2009, Polyelectrolyte coated multilayered liposomes (nanocapsules) for the treatment of Helicobacter pylori infection, Mol. Pharm., 6, 593, 10.1021/mp8002539 · DOI
  88. Jain, 2011, Recent technologies in pulsatile drug delivery systems, Biomatter, 1, 57, 10.4161/biom.1.1.17717 · DOI
  89. Jain, 2012, Folate-decorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin, Nanomed. (Lond), 7, 1311, 10.2217/nnm.12.31 · DOI
  90. Jain, 2016, Lectin-Conjugated Clarithromycin and Acetohydroxamic Acid-Loaded PLGA Nanoparticles: a Novel Approach for Effective Treatment of H. pylori, AAPS PharmSciTech., 17, 1131, 10.1208/s12249-015-0443-5 · DOI
  91. Johansson, 2013, The gastrointestinal mucus system in health and disease, Nat. Rev. Gastroenterol. Hepatol., 10, 352, 10.1038/nrgastro.2013.35 · DOI · Paper page
  92. Joshi, 2014, Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery, Eur. J. Pharmaceut. Sci., 60, 80, 10.1016/j.ejps.2014.04.014 · DOI
  93. Joshi, 2016, Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles, Drug Delivery, 23, 3492, 10.1080/10717544.2016.1199605 · DOI
  94. Jubeh, 2004, Differential Adhesion of Normal and Inflamed Rat Colonic Mucosa by Charged Liposomes, Pharmaceut. Res., 21, 447, 10.1023/B:PHAM.0000019298.29561.cd · DOI · Paper page
  95. Kagan, 2008, Systems for region selective drug delivery in the gastrointestinal tract: biopharmaceutical considerations, Expert Opin. Drug Deliv., 5, 681, 10.1517/17425247.5.6.681 · DOI · Paper page
  96. Kang, 2018, Small intestine- and colon-specific smart oral drug delivery system with controlled release characteristic, Mater. Sci. Eng. C Mater. Biol. Appl., 91, 247, 10.1016/j.msec.2018.05.052 · DOI
  97. Kararli, 1995, Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals, Biopharm Drug Dispos., 16, 351, 10.1002/bdd.2510160502 · DOI
  98. Kashyap, 2013, Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice, Gastroenterology, 144, 967, 10.1053/j.gastro.2013.01.047 · DOI · Paper page
  99. Khan, 1999, A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers. I. Manipulation Of drug release using Eudragit L100-55 and Eudragit S100 combinations, J. Control Release, 58, 215, 10.1016/S0168-3659(98)00151-5 · DOI
  100. Konturek, 2011, Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options, J. Physiol. Pharmacol., 62, 591
  101. Kriegel, 2011, Oral TNF-alpha gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease, J. Control Release, 150, 77, 10.1016/j.jconrel.2010.10.002 · DOI
  102. Kriegel, 2011, Dual TNF-alpha/Cyclin D1 Gene Silencing With an Oral Polymeric Microparticle System as a Novel Strategy for the Treatment of Inflammatory Bowel Disease, Clin. Transl. Gastroenterol., 2, e2, 10.1038/ctg.2011.1 · DOI
  103. Kshirsagar, 2012, Preparation and characterization of nanocapsules for colon-targeted drug delivery system, Pharm. Dev. Technol., 17, 607, 10.3109/10837450.2011.557732 · DOI
  104. Kumar, 2018, An Overview on Various Approaches and Recent Patents on Gastroretentive Drug Delivery Systems, Recent Pat. Drug Delivery Formul., 12, 84, 10.2174/1872211312666180308150218 · DOI
  105. Kvietys, 1999, Intestinal physiology relevant to short-bowel syndrome, Eur. J. Pediatr. Surg., 9, 196, 10.1055/s-2008-1072243 · DOI
  106. Kyd, 2008, Functional differences between M cells and enterocytes in sampling luminal antigens, Vaccine, 26, 6221, 10.1016/j.vaccine.2008.09.061 · DOI · Paper page
  107. Lahner, 2009, Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy, Alimentary Pharmacol. Ther., 29, 1219, 10.1111/j.1365-2036.2009.03993.x · DOI
  108. Lamprecht, 2001, Size-Dependent Bioadhesion of Micro- and Nanoparticulate Carriers to the Inflamed Colonic Mucosa, Pharmaceut. Res., 18, 788, 10.1023/A:1011032328064 · DOI · Paper page
  109. Lamprecht, 2001, Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease, J. Pharmacol. Exp. Ther., 299, 775
  110. Lamprecht, 2005, Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats, J. Pharmacol. Exp. Ther., 315, 196, 10.1124/jpet.105.088146 · DOI
  111. Lamprecht, 2005, A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles, J. Control Release, 104, 337, 10.1016/j.jconrel.2005.02.011 · DOI
  112. Laroui, 2010, Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model, Gastroenterology, 138, 843, 10.1053/j.gastro.2009.11.003 · DOI
  113. Laroui, 2014, Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles, Mol. Ther., 22, 69, 10.1038/mt.2013.214 · DOI
  114. Laroui, 2014, Fab'-bearing siRNA TNFalpha-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis, J. Control Release, 186, 41, 10.1016/j.jconrel.2014.04.046 · DOI
  115. Larsson, 2009, A complex, but uniform O-glycosylation of the human MUC2 mucin from colonic biopsies analyzed by nanoLC/MSn, Glycobiology, 19, 756, 10.1093/glycob/cwp048 · DOI
  116. Lautenschlager, 2013, PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease, Eur. J. Pharm. Biopharm., 85, 578, 10.1016/j.ejpb.2013.09.016 · DOI
  117. Li, 2003, Basement membrane components, J. Clin. Pathol., 56, 885, 10.1136/jcp.56.12.885 · DOI
  118. Li, 2017, Influence of Particle Geometry on Gastrointestinal Transit and Absorption following Oral Administration, ACS Appl. Mater. Interf., 9, 42492, 10.1021/acsami.7b11821 · DOI
  119. Lin, 2005, Measurement of gastrointestinal transit, Digestive Dis. Sci., 50, 989, 10.1007/s10620-005-2694-6 · DOI
  120. Ling, 2009, Oral bioavailability enhancement of a hydrophilic drug delivered via folic acid-coupled liposomes in rats, J. Pharm. Pharmacol., 61, 445, 10.1211/jpp.61.04.0005 · DOI
  121. Linskens, 2001, The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics, Scand. J. Gastroenterol. Suppl., 36, 29, 10.1080/003655201753265082 · DOI · Paper page
  122. Liu, 2005, Interaction of various pectin formulations with porcine colonic tissues, Biomaterials, 26, 5907, 10.1016/j.biomaterials.2005.03.005 · DOI
  123. Liu, 2016, Efficient mucus permeation and tight junction opening by dissociable “mucus-inert” agent coated trimethyl chitosan nanoparticles for oral insulin delivery, J. Control Release, 222, 67, 10.1016/j.jconrel.2015.12.008 · DOI
  124. Liu, 2017, pH-Responsive carriers for oral drug delivery: challenges and opportunities of current platforms, Drug Delivery, 24, 569, 10.1080/10717544.2017.1279238 · DOI · Paper page
  125. Lundquist, 2016, Oral absorption of peptides and nanoparticles across the human intestine: Opportunities, limitations and studies in human tissues, Adv. Drug Delivery Rev., 106, 256, 10.1016/j.addr.2016.07.007 · DOI
  126. Macfarlane, 2011, Fermentation in the human large intestine: its physiologic consequences and the potential contribution of prebiotics, J. Clin. Gastroenterol., S120, 10.1097/MCG.0b013e31822fecfe · DOI · Paper page
  127. Macfarlane, 1988, Contribution of the microflora to proteolysis in the human large intestine, J. Appl. Bacteriol., 64, 37, 10.1111/j.1365-2672.1988.tb02427.x · DOI · Paper page
  128. Madara, 1998, Regulation of the movement of solutes across tight junctions, Annu. Rev. Physiol., 60, 143, 10.1146/annurev.physiol.60.1.143 · DOI
  129. Mahida, 1989, Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease, Gut, 30, 1362, 10.1136/gut.30.10.1362 · DOI
  130. Maisel, 2015, Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse, J. Control Release, 197, 48, 10.1016/j.jconrel.2014.10.026 · DOI
  131. Makhlof, 2009, pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model, Eur. J. Pharm. Biopharm., 72, 1, 10.1016/j.ejpb.2008.12.013 · DOI
  132. Makhlof, 2011, Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery, Eur. J. Pharmaceut. Sci., 42, 445, 10.1016/j.ejps.2010.12.007 · DOI
  133. Makhlof, 2011, In vitro and in vivo evaluation of WGA-carbopol modified liposomes as carriers for oral peptide delivery, Eur. J. Pharm. Biopharm., 77, 216, 10.1016/j.ejpb.2010.12.008 · DOI · Paper page
  134. Managuli, 2018, Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs, Expert Opin. Drug Deliv., 15, 787, 10.1080/17425247.2018.1503249 · DOI
  135. Mandal, 2016, Gastro-retentive drug delivery systems and their in vivo success: a recent update, Asian J. Pharmaceut. Sci., 11, 575, 10.1016/j.ajps.2016.04.007 · DOI
  136. Mane, 2012, Biodistribution and endocytosis of ICAM-1-targeting antibodies versus nanocarriers in the gastrointestinal tract in mice, Int. J. Nanomed., 7, 4223, 10.2147/ijn.s34105 · DOI
  137. Manocha, 2005, Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target, Vaccine, 23, 5599, 10.1016/j.vaccine.2005.06.031 · DOI
  138. Marieb, 2010, Human Anatomy and Physiology.
  139. Marquez Ruiz, 2012, Azo-reductase activated budesodine prodrugs for colon targeting, Bioorg. Med. Chem. Lett., 22, 7573, 10.1016/j.bmcl.2012.10.006 · DOI
  140. Martinez, 2002, A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals, J. Clin. Pharmacol., 42, 620, 10.1177/00970002042006005 · DOI · Paper page
  141. McConnell, 2008, An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man, J. Controlled Release, 130, 154, 10.1016/j.jconrel.2008.05.022 · DOI
  142. McKeage, 2002, Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults, Drugs, 62, 2263, 10.2165/00003495-200262150-00015 · DOI
  143. Meissner, 2006, Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery, Int. J. Pharm., 316, 138, 10.1016/j.ijpharm.2006.01.032 · DOI
  144. Miller, 2007, Intestinal M cells: the fallible sentinels, World J. Gastroenterol., 13, 1477, 10.3748/wjg.v13.i10.1477 · DOI
  145. Miranda, 2007, Investigation of the influence of particle size on the excipient percolation thresholds of HPMC hydrophilic matrix tablets, J. Pharm. Sci., 96, 2746, 10.1002/jps.20912 · DOI
  146. Moss, 2018, The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery, Expert Rev. Gastroenterol. Hepatol., 12, 223, 10.1080/17474124.2018.1399794 · DOI
  147. Moulari, 2008, The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis, Biomaterials, 29, 4554, 10.1016/j.biomaterials.2008.08.009 · DOI
  148. Murakami, 2017, Absorption sites of orally administered drugs in the small intestine, Expert Opin. Drug Discovery, 12, 1219, 10.1080/17460441.2017.1378176 · DOI
  149. Ngwuluka, 2015, An optimized gastroretentive nanosystem for the delivery of levodopa, Int. J. Pharm., 494, 49, 10.1016/j.ijpharm.2015.08.014 · DOI
  150. Niebel, 2012, Nanoparticle-based clodronate delivery mitigates murine experimental colitis, J. Control Release, 160, 659, 10.1016/j.jconrel.2012.03.004 · DOI
  151. Nugent, 2001, Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs, Gut, 48, 571, 10.1136/gut.48.4.571 · DOI
  152. Nykanen, 2001, Citric acid as excipient in multiple-unit enteric-coated tablets for targeting drugs on the colon, Int. J. Pharm., 229, 155, 10.1016/S0378-5173(01)00839-0 · DOI
  153. Oz, 2008, Application of prodrugs to inflammatory diseases of the gut, Molecules, 13, 452, 10.3390/molecules13020452 · DOI
  154. Patel, 2014, Mucosal Inflammatory Response to Salmonella typhimurium Infection, Front. Immunol., 5, 10.3389/fimmu.2014.00311 · DOI
  155. Patel, 2011, Design and evaluation of colon targeted modified pulsincap delivery of 5-fluorouracil according to circadian rhythm, Int. J. Pharmaceut. Invest., 1, 172, 10.4103/2230-973X.85969 · DOI
  156. Patel, 2014, Getting into the colon: approaches to target colorectal cancer, Expert Opin. Drug Delivery, 11, 1343, 10.1517/17425247.2014.927440 · DOI
  157. Patel, 2015, Colon: a gateway for chronotherapeutic drug delivery systems, Expert Opin. Drug Delivery, 12, 1389, 10.1517/17425247.2015.1060217 · DOI
  158. Pawar, 2011, Gastroretentive dosage forms: a review with special emphasis on floating drug delivery systems, Drug Deliv., 18, 97, 10.3109/10717544.2010.520354 · DOI
  159. Peterson, 2002, A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease, Am. J. Gastroenterol., 97, 1755, 10.1111/j.1572-0241.2002.05837.x · DOI · Paper page
  160. Podolsky, 2002, Inflammatory bowel disease, New Engl. J. Med., 347, 417, 10.1056/NEJMra020831 · DOI
  161. Prajapati, 2018, Oral bioavailability enhancement of agomelatine by loading into nanostructured lipid carriers: Peyer's patch targeting approach, Int. J. Nanomed., 13, 35, 10.2147/IJN.S124703 · DOI
  162. Rafii, 1990, Azoreductase activity of anaerobic bacteria isolated from human intestinal microflora, Appl. Environ. Microbiol., 56, 2146, 10.1128/AEM.56.7.2146-2151.1990 · DOI
  163. Ramteke, 2008, Clarithromycin- and omeprazole-containing gliadin nanoparticles for the treatment of Helicobacter pylori, J. Drug Targeting, 16, 65, 10.1080/10611860701733278 · DOI
  164. Ramteke, 2008, Triple therapy-based targeted nanoparticles for the treatment of Helicobacter pylori, J. Drug Targeting, 16, 694, 10.1080/10611860802295839 · DOI
  165. Ramteke, 2009, Amoxicillin, clarithromycin, and omeprazole based targeted nanoparticles for the treatment of H. pylori, J. Drug Targeting, 17, 225, 10.1080/10611860902718649 · DOI
  166. Rana, 2013, Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease, Digestive Dis. Sci., 58, 2594, 10.1007/s10620-013-2694-x · DOI
  167. Rao, 2004, Objective evaluation of small bowel and colonic transit time using pH telemetry in athletes with gastrointestinal symptoms, Br. J. Sports Med., 38, 482, 10.1136/bjsm.2003.006825 · DOI · Paper page
  168. Reinholz, 2018, The challenges of oral drug delivery via nanocarriers, Drug Delivery, 25, 1694, 10.1080/10717544.2018.1501119 · DOI
  169. Reinus, 2014, Gastrointestinal Anatomy and Physiology: The Essentials, 10.1002/9781118833001 · DOI · Paper page
  170. Reix, 2012, In vitro uptake evaluation in Caco-2 cells and in vivo results in diabetic rats of insulin-loaded PLGA nanoparticles, Int. J. Pharm., 437, 213, 10.1016/j.ijpharm.2012.08.024 · DOI
  171. Rosenthal, 2012, The effect of chitosan on transcellular and paracellular mechanisms in the intestinal epithelial barrier, Biomaterials, 33, 2791, 10.1016/j.biomaterials.2011.12.034 · DOI
  172. Rouge, 1996, Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery, Int. J. Pharmaceut., 136, 117, 10.1016/0378-5173(96)85200-8 · DOI
  173. Rouge, 1998, Comparative pharmacokinetic study of a floating multiple-unit capsule, a high-density multiple-unit capsule and an immediate-release tablet containing 25 mg atenolol, Pharm. Acta Helvetiae, 73, 81, 10.1016/S0031-6865(97)00050-2 · DOI
  174. Rubinstein, 1994, Mucus gel thickness and turnover in the gastrointestinal tract of the rat: response to cholinergic stimulus and implication for mucoadhesion, Pharmaceut. Res., 11, 794, 10.1023/A:1018961204325 · DOI
  175. Rubinstein, 2000, Natural polysaccharides as targeting tools of drugs to the human colon, Drug Dev. Res., 50, 435, 10.1002/1098-2299(200007/08)50:3/4<435::AID-DDR26>3.0.CO;2-5 · DOI
  176. Saftig, 2009, Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function, Nat. Rev. Mol. Cell Biol., 10, 623, 10.1038/nrm2745 · DOI · Paper page
  177. Saltzman, 1994, Antibody diffusion in human cervical mucus, Biophys. J., 66, 508, 10.1016/S0006-3495(94)80802-1 · DOI
  178. Sangalli, 2001, In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery, J. Control Release, 73, 103, 10.1016/S0168-3659(01)00291-7 · DOI
  179. Sarparanta, 2012, The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems, Biomaterials, 33, 3353, 10.1016/j.biomaterials.2012.01.029 · DOI
  180. Sartor, 2008, Microbial influences in inflammatory bowel diseases, Gastroenterology, 134, 577, 10.1053/j.gastro.2007.11.059 · DOI · Paper page
  181. Sartor, 2010, Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis, Gastroenterology, 139, 1816, 10.1053/j.gastro.2010.10.036 · DOI · Paper page
  182. Sasaki, 1997, Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: colonic luminal pH in normal subjects and patients with Crohn's disease, Am. J. Gastroenterol., 92, 114
  183. Sathyan, 2000, Effect of dosing time on the total intestinal transit time of non-disintegrating systems, Int. J. Pharm., 204, 47, 10.1016/S0378-5173(00)00472-5 · DOI
  184. Scheline, 1973, Metabolism of foreign compounds by gastrointestinal microorganisms, Pharmacol. Rev., 25, 451
  185. Schmidt, 1996, Effect of intestinal resection on human small bowel motility, Gut, 38, 859, 10.1136/gut.38.6.859 · DOI
  186. Schmidt, 2013, Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients, J. Control Release, 165, 139, 10.1016/j.jconrel.2012.10.019 · DOI
  187. Sercombe, 2015, Advances and Challenges of Liposome Assisted Drug Delivery, Front. Pharmacol., 6, 10.3389/fphar.2015.00286 · DOI
  188. Shah, 2011, Polysaccharides: a targeting strategy for colonic drug delivery, Expert Opin. Drug Deliv., 8, 779, 10.1517/17425247.2011.574121 · DOI
  189. Shahdadi Sardo, 2019, A review on 5-aminosalicylic acid colon-targeted oral drug delivery systems, Int. J. Pharm., 558, 367, 10.1016/j.ijpharm.2019.01.022 · DOI · Paper page
  190. Shakweh, 2004, Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery, Expert Opin. Drug Delivery, 1, 141, 10.1517/17425247.1.1.141 · DOI
  191. Sharma, 2018, Development and Characterization of Gastroretentive High-Density Pellets Lodged With Zero Valent Iron Nanoparticles, J. Pharm. Sci., 107, 2663, 10.1016/j.xphs.2018.06.014 · DOI
  192. Sharpe, 2014, Therapeutic applications of hydrogels in oral drug delivery, Expert Opin. Drug Deliv., 11, 901, 10.1517/17425247.2014.902047 · DOI · Paper page
  193. Shen, 2002, Intestinal patches for oral drug delivery, Pharmaceut. Res., 19, 391, 10.1023/A:1015118923204 · DOI
  194. Shreya, 2018, Active Targeting of Drugs and Bioactive Molecules via Oral Administration by Ligand-Conjugated Lipidic Nanocarriers: Recent Advances, AAPS PharmSciTech., 20, 15, 10.1208/s12249-018-1262-2 · DOI
  195. Siepmann, 2001, Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC), Adv. Drug Delivery Rev., 48, 139, 10.1016/S0169-409X(01)00112-0 · DOI
  196. Simmonds, 1992, Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease, Gastroenterology, 103, 186, 10.1016/0016-5085(92)91112-H · DOI
  197. Singh, 2015, Combinatorial Approach of Antigen Delivery Using M Cell-Homing Peptide and Mucoadhesive Vehicle to Enhance the Efficacy of Oral Vaccine, Mol. Pharm., 12, 3816, 10.1021/acs.molpharmaceut.5b00265 · DOI
  198. Singodia, 2012, Investigations into an alternate approach to target mannose receptors on macrophages using 4-sulfated N-acetyl galactosamine more efficiently in comparison with mannose-decorated liposomes: an application in drug delivery, Nanomedicine, 8, 468, 10.1016/j.nano.2011.07.002 · DOI
  199. Sinha, 2001, Polysaccharides in colon-specific drug delivery, Int. J. Pharm., 224, 19, 10.1016/S0378-5173(01)00720-7 · DOI · Paper page
  200. Spiller, 1988, Further characterisation of the ‘ileal brake' reflex in man–effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY, Gut, 29, 1042, 10.1136/gut.29.8.1042 · DOI

200 of 251 shown

Cited by

Sorted by citations

See all 527

Metadata

Authors
Hua, S.
Venue
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Published
2020-04-28
Volume
11
ISSN
1663-9812
DOI
10.3389/fphar.2020.00524
PMC
PMC7212533
Cited by
527
References
12
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review